Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Inflammatory myofibroblastic tumor (IMT) is a rare tumor with a particular histological pattern of myofibroblasts and mixed inflammatory infiltrate. IMT has been rarely described in association with malignancy. This case report is of a 16-year-old male who had Hodgkin's disease (stage IVA) and who after chemotherapy and radiotherapy developed IMT, 16 months post completion of therapy. The IMT was in the lung in an area which was previously involved with HD and had undergone radiotherapy. PET imaging with F(18)FDG was used in the initial diagnosis and has been used in follow-up after full surgical resection of the lesion.
 ...
PMID:Pulmonary inflammatory myofibroblastic tumor after Hodgkin's lymphoma and application of PET imaging. 1852 95

Fluorodeoxyglucose positron emission tomography (FDG-PET) is now considered the most accurate tool for the assessment of treatment response and prognosis in patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma. This article discusses the potential and limitations of FDG-PET for response assessment in malignant lymphoma during chemotherapy (interim PET) and at the end of chemotherapy. Interim PET is used to predict the likelihood for a complete response at the end of such therapy. End-of-treatment PET aims to establish the completeness of response or the presence of residual viable tumor tissue. Until the results of ongoing clinical trials emerge over the next 5 years, interim PET should be considered investigational and should not be used for patient management outside of study protocols.
 ...
PMID:PET imaging for response assessment in lymphoma: potential and limitations. 1861 78

Successful treatment of Hodgkin lymphomas and non-Hodgkin lymphomas depends on accurate staging and prognostic estimations, as well as evaluation of response to therapy as early after initiation as possible. We focus on several aspects of molecular imaging and therapy that affect the management of patients who have lymphoma. First, we review prior use of gallium-67 citrate for evaluation of lymphoma patients, mainly from a historical perspective, since it was the mainstream lymphoma functional imaging tracer for decades. Next, we review current clinical uses of 18F Fluoro-2-Deoxyglucose (18F FDG) PET and PET/CT for evaluation of lymphoma patients and use of radioimmunotherapy in lymphoma. Finally, we discuss advances in molecular imaging that may herald the next generation of PET radiotracers after 18F FDG.
 ...
PMID:Perspectives of molecular imaging and radioimmunotherapy in lymphoma. 1861 79

Mantle cell lymphoma (MCL) is a rare but aggressive non-Hodgkin lymphoma subtype with a poor prognosis; most patients relapse despite initial response to therapy. Response was traditionally evaluated by computed tomography (CT), but the introduction of [(18)F]Fluorine-Deoxyglucose Positron Emission Tomography (PET) changed response assessment in aggressive lymphoma. However, the value of PET-evaluation in MCL has not been studied yet. Therefore, PET- and CT-findings were investigated in 37 patients with MCL (239 scans) and categorised following standardised response criteria for CT-evaluation (IWC-criteria), PET-evaluation (EORTC-criteria) and combined PET/CT-evaluation (IWC + PET-criteria). FDG-PET showed a high sensitivity for the detection of deposits of MCL and a higher FDG-uptake was shown in patients with the more aggressive blastoid-variant of MCL versus common MCL. However, routine use of PET for end-of-treatment response assessment in MCL cannot be recommended because CT- and PET-based designation systems had equivalent prognostic value. PET-based end-of-treatment response assessment only provided additional information over CT-based response assessment in a subpopulation of patients with highly FDG-avid MCL. PET allowed early detection of preclinical relapse during post-therapy surveillance, but the therapeutic consequences of such information are currently unclear.
 ...
PMID:Positron emission tomography in mantle cell lymphoma. 1879

The high negative predictive value of FDG-PET in therapy control of Hodgkin lymphoma is proven by the data acquired up to now. Thus, the analysis of the HD15 trial has shown that consolidation radiotherapy might be omitted in PET negative patients after effective chemotherapy. Further response adapted therapy guided by PET seems to be a promising approach in reducing the toxicity for patients undergoing chemotherapy. The criteria used for the PET interpretation have been standardized by the German study groups for Hodgkin lymphoma patients and will be reevaluated in the current studies.
 ...
PMID:[FDG-PET in Hodgkin lymphoma]. 1905 96

Assessing the response to treatment as soon after treatment initiation is one of the key reasons for imaging lymphoma patients. The optimal time after initiating treatment for assessing response to treatment has yet to be determined. Therefore, we were prompted to review our experience with serial (18)F-FDG PET/CT in patients undergoing treatment for Hodgkin's disease (HD) and non Hodgkin's lymphoma (NHL). This is a retrospective study (Feb 2003 - Oct 2004) of 20 patients, 11 men and 9 women, with age range of 7-75 years with diagnosis of HD (10) and NHL (10), who had PET/CT at our institution prior, during and at the completion of therapy. Restaging PET/CT was done after 2 cycles of chemotherapy in 10 patients (group A) and after 4 cycles of chemotherapy in 10 pts (group B). A total of 60 scans were reviewed. The DeltaSUV from baseline to first PET/CT was on average 67.6% in group A and 75.1% in group B. This had no statistical significance (P value: 0.31). The DeltaSUV from baseline to post-therapy PET/CT was on average 72.9% in group A and 79.8% in group B. This difference also had no statistical significance (P value: 0.24). The correlation coefficient was 0.98 in group A and 0.80 in group B. Results of PET/CT after 2 cycles of chemotherapy did not statistically differ from the results of PET/CT after 4 cycles of chemotherapy. These results need to be confirmed in larger, prospective, randomized trials.
 ...
PMID:(18)F-FDG-PET/CT evaluation of response to treatment in lymphoma: when is the optimal time for the first re-evaluation scan? 1908 57

18Fluoro-deoxyglucose positron emission tomography (FDG-PET) imaging has been widely incorporated into the management of systemic non-Hodgkin lymphoma. However, its utility in primary central nervous system lymphoma (PCNSL) is unclear. We report 28 PCNSL patients who underwent brain FDG-PET to inform clinical management. Baseline PET imaging demonstrated hypermetabolism consistent with aggressive lymphoma in 75% (9/12) of patients. FDG-PET used for response assessment or the interpretation of nonspecific magnetic resonance imaging abnormalities showed hypermetabolism in 50% (10/20) of patients, which was important in guiding further management. This data suggests that FDG-PET imaging in PCNSL is useful and may have a role in response assessment.
 ...
PMID:Utility of brain FDG-PET in primary CNS lymphoma. 1919 66

A 28-year-old Japanese man presented with a 14-month history of right pelvic and lumbar pain. Despite normal findings on X-ray and CT scan at a previous hospital, sternal tumor had arisen and fever, night sweat, and weight loss developed 5 months before admission. Core needle biopsy of the sternal tumor was performed and a diagnosis of Hodgkin lymphoma (HL) (mixed cellularity) was made. FDG-PET scan demonstrated increased FDG uptake in the sternum, the right ilium, the right 9(th) rib, and the lower edge of the left scapula, but there were no other apparent lesions. Neither bone marrow biopsy nor cerebrospinal fluid examination showed infiltration of lymphoma cells. ABVD was started and the symptoms resolved immediately. After 6 cycles of ABVD, the patient achieved complete remission and local radiotherapy for the right ilium was added. Primary osseous HL confined to the bone is so rare that only 16 cases have been reported worldwide to date, with none of these cases being from Japan. Since there have not yet been any characteristic symptoms or laboratory findings identified, the diagnosis of osseous HL is difficult and may be delayed. Although systemic chemotherapy appears to have been effective in the reported cases, more cases should be reviewed to clarify its pathophysiological features.
 ...
PMID:[Primary multifocal osseous Hodgkin lymphoma]. 1926 1

The Italian Society of Hematology (SIE), the Italian Society of Experimental Haematology (SIES) and the Italian Group for Bone Marrow Transplantation (GITMO) commissioned a project to develop practice guidelines for the initial work-up, therapy and follow-up of classical Hodgkin's lymphoma. Key questions to the clinical evaluation and treatment of this disease were formulated by an Advisory Committee, discussed and approved by an Expert Panel (EP) composed of senior hematologists and one radiotherapist. After a comprehensive and systematic literature review, the EP recommendations were graded according to their supporting evidence. An explicit approach to consensus methodologies was used for evidence interpretation and for producing recommendations in the absence of a strong evidence. The EP decided that the target domain of the guidelines should include only classical Hodgkin's lymphoma, as defined by the WHO classification, and exclude lymphocyte predominant histology. Distinct recommendations were produced for initial work-up, first-line therapy of early and advanced stage disease, monitoring procedures and salvage therapy, including hemopoietic stem cell transplant. Separate recommendations were formulated for elderly patients. Pre-treatment volumetric CT scan of the neck, thorax, abdomen, and pelvis is mandatory, while FDG-PET is recommended. As to the therapy of early stage disease, a combined modality approach is still recommended with ABVD followed by involved-field radiotherapy; the number of courses of ABVD will depend on the patient risk category (favorable or unfavorable). Full-term chemotherapy with ABVD is recommended in advanced stage disease; adjuvant radiotherapy in patients without initial bulk who achieved a complete remission is not recommended. In the elderly, chemotherapy regimens more intensive than ABVD are not recommended. Early evaluation of response with FDG-PET scan is suggested. Relapsed or refractory patients should receive high-dose chemotherapy and autologous hemopoietic stem cells transplant. Allogeneic transplant is recommended in patients relapsing after autologous transplant. All fertile patients should be informed of the possible effects of therapy on gonadal function and fertility preservation measures should be taken before the initiation of therapy.
 ...
PMID:Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up. 1927 66

In this case we show the significance of dual time point PET in determining the nature of an abdominal process in a 67-year-old man with a newly diagnosed adenocarcinoma of the esophagus. Whole body PET/CT detected abnormal uptake in the distal part of the esophagus. In addition, focally increased FDG uptake was detected in the right abdomen. The late PET images of the abdomen showed an increase in the SUV resulting in this lesion being evaluated as malignant. The final pathology of the abdominal mass revealed a follicular B-Cell non-Hodgkin lymphoma grade I.
 ...
PMID:Dual-time F-18 FDG-PET/CT imaging for diagnosis of occult non-Hodgkin lymphoma in a patient with esophageal cancer. 1935 82


<< Previous 1 2 3 4 5 6 7 8 9 10